Acute Leukemia

Disclaimer: This clinical reference provides comprehensive, evidence-based medical information for educational and informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Clinicians must exercise their independent medical judgment in the context of individual patient circumstances, considering all available clinical data, and in consultation with specialists as appropriate. Treatment decisions for acute leukemia are complex and should be made by a multidisciplinary team.

---

Overview

• Definition: Acute leukemia (AL) refers to a group of aggressive hematologic malignancies characterized by the rapid, uncontrolled proliferation and accumulation of immature hematopoietic cells (blasts) in the bone marrow and peripheral blood. This leads to bone marrow failure, resulting in cytopenias (anemia, thrombocytopenia, neutropenia) and infiltration of various organs by leukemic cells.
• Epidemiology:
  • Incidence: Approximately 1.1% of all new cancer cases in the United States.
  • Acute Myeloid Leukemia (AML): Accounts for about 80% of adult acute leukemias. Incidence increases with age, with a median age at diagnosis of around 68 years. More common in males than females.
  • Acute Lymphoblastic Leukemia (ALL): Primarily a disease of childhood, with a peak incidence between ages 1-5 years. It is the most common childhood cancer. A second, smaller peak occurs in adults over 50 years. ALL accounts for about 20% of adult acute leukemias.
• Classification:
  • Major Types:
    • Acute Myeloid Leukemia (AML): Originates from myeloid progenitor cells.
    • Acute Lymphoblastic Leukemia (ALL): Originates from lymphoid progenitor cells (either B-cell or T-cell lineage).
  • World Health Organization (WHO) Classification (2016/2022): The current standard, integrating morphology, immunophenotype, cytogenetics, and molecular genetics. It defines specific categories based on recurrent genetic abnormalities, myelodysplasia-related changes, and therapy-related origins.
    • AML categories: AML with recurrent genetic abnormalities (e.g., t(8;21), inv(16), t(15;17) [APL], NPM1 mutation, CEBPA mutation, RUNX1 mutation), AML with myelodysplasia-related changes, Therapy-related AML (t-AML), AML not otherwise specified (NOS), Myeloid sarcoma, Myeloid proliferations associated with Down syndrome.
    • ALL categories: ALL with recurrent genetic abnormalities (e.g., BCR-ABL1 fusion, KMT2A rearrangement, ETV6-RUNX1 fusion, Ph-like ALL), B-lymphoblastic leukemia/lymphoma NOS, T-lymphoblastic leukemia/lymphoma NOS.
  • French-American-British (FAB) Classification: An older system based purely on morphology and cytochemistry, now largely superseded by WHO but still sometimes referenced (e.g., M0-M7 for AML, L1-L3 for ALL).

Pathophysiology

• Mechanism: Acute leukemia arises from a clonal expansion of a single transformed hematopoietic stem or progenitor cell. This cell acquires genetic mutations that impair its ability to differentiate into mature blood cells and promote uncontrolled proliferation and survival. The accumulation of these immature blasts in the bone marrow suppresses normal hematopoiesis, leading to bone marrow failure (anemia, neutropenia, thrombocytopenia). The blasts can also infiltrate extramedullary sites.
  • Genetic Abnormalities: Key driver mutations vary by leukemia type.
    • AML: Common mutations include FLT3-ITD, NPM1, CEBPA, IDH1/2, KIT, TP53, RUNX1, ASXL1, and chromosomal translocations like t(8;21), inv(16), t(15;17). These mutations affect genes involved in transcription, signaling, epigenetics, and DNA repair.
    • ALL: Common alterations include BCR-ABL1 fusion (Philadelphia chromosome), KMT2A (MLL) rearrangements, ETV6-RUNX1 (TEL-AML1) fusion, PAX5, IKZF1 deletions, NOTCH1 mutations (T-ALL).
• Risk Factors:
  • Genetic Syndromes: Down syndrome (increased risk of AML and ALL), Fanconi anemia, Bloom syndrome, Ataxia-telangiectasia, Li-Fraumeni syndrome, Neurofibromatosis type 1, Kostmann syndrome, Shwachman-Diamond syndrome.
  • Previous Cancer Treatment: Prior chemotherapy (especially alkylating agents like cyclophosphamide, etoposide, or topoisomerase II inhibitors) or radiation therapy can cause therapy-related AML (t-AML) or t-ALL.
  • Exposure to Chemicals/Radiation: Chronic exposure to certain chemicals (e.g., benzene), high-dose radiation exposure.
  • Hematologic Disorders: Pre-existing myeloid disorders such as Myelodysplastic Syndromes (MDS) or Myeloproliferative Neoplasms (MPN) can transform into AML.
  • Lifestyle Factors: Smoking (increases AML risk).
  • Age: Older age is a significant risk factor for AML.
• Protective Factors: No specific protective factors are definitively established beyond avoiding known risk factors like benzene exposure or smoking. Genetic predisposition makes primary prevention challenging.

Clinical Presentation

Signs and Symptoms

Symptoms typically develop rapidly over days to weeks, reflecting bone marrow failure or organ infiltration.

• Cardinal Features (due to bone marrow failure):
  • Anemia (low red blood cells): Fatigue, weakness, pallor, dyspnea on exertion, lightheadedness.
  • Thrombocytopenia (low platelets): Easy bruising, petechiae (small, pinpoint red spots), purpura, epistaxis (nosebleeds), gingival bleeding, menorrhagia, or more severe hemorrhage.
  • Neutropenia (low neutrophils): Recurrent infections (bacterial, fungal, viral), often with fever (febrile neutropenia), oral ulcers, cellulitis, pneumonia.
• Early Signs: Often non-specific and mimic common viral infections: malaise, low-grade fever, general fatigue, loss of appetite, mild joint or bone pain.
• Advanced Signs (due to organ infiltration):
  • Constitutional: Weight loss, night sweats.
  • Lymphadenopathy: Swollen lymph nodes (more common in ALL).
  • Hepatosplenomegaly: Enlarged liver and/or spleen.
  • Gingival Hypertrophy: Swollen, bleeding gums (especially in acute monocytic leukemia, AML-M4/M5).
  • Skin Infiltrates (Leukemia Cutis): Reddish-blue or violaceous nodules or plaques.
  • Bone Pain/Arthralgia: Especially in children with ALL, due to marrow expansion or periosteal infiltration.
  • Central Nervous System (CNS) Involvement: Headache, nausea, vomiting, visual changes, cranial nerve palsies, seizures, altered mental status (more common in ALL, particularly T-ALL, and monocytic AML).
  • Leukostasis: Extremely high white blood cell count (typically >100,000/µL, but can occur at lower counts with monocytic blasts) leading to impaired microcirculation. Symptoms include dyspnea, hypoxia, visual disturbances, headache, confusion, somnolence. A medical emergency.
  • Mediastinal Mass: Respiratory distress, stridor, dysphagia (especially in T-ALL).
  • Testicular Involvement: Painless swelling (in ALL).
• Atypical Presentations: Isolated extramedullary disease (myeloid sarcoma/chloroma) without significant peripheral blood or bone marrow involvement, or very mild symptoms despite significant disease.

Physical Examination

• Inspection:
  • Pallor: Indicative of anemia.
  • Petechiae/Ecchymoses: Evidence of thrombocytopenia.
  • Jaundice: Rarely, due to hepatic infiltration or hemolysis.
  • Gingival Hypertrophy: Swollen gums, especially in AML with monocytic differentiation.
  • Lymphadenopathy: Palpable enlarged lymph nodes (cervical, axillary, inguinal).
  • Skin Lesions: Nodules, papules, or plaques (leukemia cutis).
  • Signs of Infection: Cellulitis, oral candidiasis, perirectal abscess.
• Palpation:
  • Hepatosplenomegaly: Enlarged liver and/or spleen, often soft or firm.
  • Lymphadenopathy: Palpable nodes.
  • Sternal Tenderness: Due to marrow expansion.
  • Testicular Swelling: In ALL.
• Special Tests:
  • Funduscopic Examination: May reveal retinal hemorrhages, white-centered Roth spots, leukemic infiltrates, or papilledema (suggestive of increased intracranial pressure).
  • Neurological Examination: For signs of CNS involvement (cranial nerve palsies, motor/sensory deficits, altered mental status).

Diagnostic Approach

History Taking

• Key Questions:
  • Onset and Duration: How quickly did symptoms develop? (Acute onset common).
  • Specific Symptoms: Fatigue, fever, bruising, bleeding, infections, bone pain, weight loss, night sweats.
  • Past Medical History: Previous cancer, chemotherapy/radiation, genetic syndromes, autoimmune conditions, history of MDS/MPN.
  • Medications: Including over-the-counter and supplements.
  • Family History: Any family history of hematologic malignancies or genetic syndromes.
  • Occupational/Environmental Exposures: Benzene, pesticides.
  • Travel History: For infectious disease risk.
• Red Flags: Rapidly progressive symptoms of bone marrow failure (severe fatigue, recurrent fevers, spontaneous bleeding), unexplained pancytopenia or very high/low WBC count with blasts on peripheral smear, new onset neurologic deficits or signs of leukostasis.

Laboratory Tests

• First-Line:
  • Complete Blood Count (CBC) with Differential:
    • Anemia: Usually normocytic, normochromic.
    • Thrombocytopenia: Common, often severe (<20,000/µL).
    • White Blood Cell (WBC) Count: Highly variable; can be very high (>100,000/µL), normal, or low (leukopenia).
    • Differential: Presence of circulating blasts (immature cells) in the peripheral blood is the hallmark of AL. Blasts are typically at least 20% of the peripheral white cells, but diagnosis can be made at lower percentages with specific genetic findings or if there is clear evidence of myelodysplastic syndrome progression.
  • Peripheral Blood Smear Review: Crucial for confirmation of blasts, assessment of blast morphology, and identification of other cytopenias or dysplastic features.
  • Basic Metabolic Panel (BMP): Assess renal function, electrolytes.
  • Liver Function Tests (LFTs): Assess hepatic function.
  • Lactate Dehydrogenase (LDH): Often elevated due to high cell turnover.
  • Uric Acid: May be elevated, indicating high cell turnover and risk of tumor lysis syndrome.
  • Coagulation Studies (PT/aPTT/Fibrinogen): Essential, especially to rule out Disseminated Intravascular Coagulation (DIC), particularly common in Acute Promyelocytic Leukemia (APL, AML M3).
• Confirmatory (and for classification/prognosis):
  • Bone Marrow Aspiration and Biopsy:
    • Morphology: Required for diagnosis. Diagnosis of AML/ALL typically requires ≥20% blasts in the bone marrow or peripheral blood, or presence of specific recurrent genetic abnormalities (e.g., t(15;17) for APL) regardless of blast count.
    • Cytochemistry: Stains (e.g., Myeloperoxidase for AML, PAS for ALL) to help differentiate myeloid from lymphoid blasts.
    • Immunophenotyping by Flow Cytometry: Essential for lineage assignment (myeloid, B-lymphoid, T-lymphoid), determination of specific markers (e.g., CD34, CD117, CD13, CD33 for AML; CD10, CD19, CD20, CD22 for B-ALL; CD2, CD3, CD5, CD7 for T-ALL), and detection of minimal residual disease (MRD).
    • Cytogenetics/Fluorescence In Situ Hybridization (FISH): Identify recurrent chromosomal abnormalities (e.g., t(8;21), inv(16), t(15;17), t(9;22) [BCR-ABL1], MLL rearrangements). Crucial for risk stratification and treatment planning.
    • Molecular Genetics: Detect specific gene mutations (FLT3-ITD/TKD, NPM1, CEBPA, IDH1/2, KIT, TP53, etc. for AML; IKZF1, CRLF2, NOTCH1 for ALL) influencing prognosis and guiding targeted therapy.
  • Lumbar Puncture (LP) with CSF Analysis: For ALL, mandatory at diagnosis for CNS risk assessment and prophylaxis. For AML, typically done only if there are neurological symptoms or with specific high-risk features (e.g., monocytic AML). CSF is analyzed for cell count, protein, glucose, and cytology (presence of blasts).
• Monitoring:
  • CBC with Differential: Regularly during treatment to assess counts, nadirs, and recovery.
  • Bone Marrow Biopsy: Performed after induction chemotherapy to assess remission status (CR: <5% blasts in marrow, no blasts in peripheral blood, recovery of normal hematopoiesis) and at subsequent time points (e.g., before consolidation, before transplant).
  • Minimal Residual Disease (MRD) Testing: Highly sensitive molecular or flow cytometric techniques to detect residual leukemic cells not seen by conventional microscopy. MRD-negativity is a strong prognostic factor and can guide treatment decisions.
  • Tumor Lysis Syndrome (TLS) Labs: Daily monitoring of uric acid, potassium, phosphate, calcium, creatinine during early induction.
  • Infection Markers: Procalcitonin, C-reactive protein, blood cultures, fungal markers (beta-D-glucan, galactomannan) as indicated for febrile neutropenia.

Imaging

• Recommended:
  • Chest X-ray (CXR): To assess for mediastinal mass (especially in T-ALL), pneumonia, or pulmonary infiltrates.
  • Computed Tomography (CT) Scans:
    • Chest/Abdomen/Pelvis: To assess for lymphadenopathy, hepatosplenomegaly, and extramedullary disease.
  • Echocardiogram: Baseline assessment of cardiac function before anthracycline therapy.
• Advanced:
  • Magnetic Resonance Imaging (MRI):
    • Brain/Spine: Indicated for patients with neurological symptoms suggestive of CNS involvement, or as part of routine staging for high-risk ALL (e.g., T-ALL, hyperleukocytosis, high-risk cytogenetics).
  • Positron Emission Tomography-Computed Tomography (PET-CT): Not routinely used for diagnosis or staging of acute leukemia but may be considered for evaluating specific extramedullary disease sites or myeloid sarcoma.

Management

Acute leukemia is a medical emergency requiring prompt diagnosis and initiation of treatment. Management involves intensive chemotherapy, targeted therapies, and extensive supportive care.

Acute Management (Prior to or During Early Induction)

• Immediate:
  • Stabilization: Assess airway, breathing, circulation.
  • Transfusion Support:
    • Red Blood Cells (PRBCs): For symptomatic anemia (e.g., hemoglobin <7-8 g/dL, or higher if symptomatic).
    • Platelets: For severe thrombocytopenia (e.g., <10,000/µL to prevent spontaneous bleeding, or <20,000-50,000/µL if active bleeding or before invasive procedures).
  • Broad-Spectrum Antibiotics: Initiate immediately for any signs of febrile neutropenia (fever ≥38.3°C (101°F) or ≥38.0°C (100.4°F) for >1 hour with ANC <500 cells/µL). Common initial regimens include cefepime, piperacillin-tazobactam, or meropenem, with vancomycin added if central line infection is suspected or Gram-positive cocci are seen.
• Stabilization:
  • Hydration: Aggressive intravenous hydration (e.g., 2-3 L/m²/day) to prevent tumor lysis syndrome (TLS).
  • Tumor Lysis Syndrome Prophylaxis:
    • Allopurinol: 300 mg PO daily (inhibits xanthine oxidase, reducing uric acid production).
    • Rasburicase (uricase): 0.15-0.2 mg/kg IV single dose (metabolizes uric acid to allantoin, which is more soluble). Indicated for high-risk patients (high WBC, high LDH, elevated uric acid, pre-existing renal dysfunction) or established TLS.
  • Management of Coagulopathy: Transfusion of platelets, cryoprecipitate (for fibrinogen <100 mg/dL), fresh frozen plasma as needed, particularly in APL where DIC is common.
• Emergency:
  • Leukapheresis: Indicated for symptomatic hyperleukocytosis (WBC usually >100,000/µL, especially in AML with monocytic differentiation at lower counts). Aims to rapidly reduce WBC count to prevent or alleviate symptoms of leukostasis (respiratory distress, neurological changes). Not indicated for asymptomatic hyperleukocytosis as it does not improve long-term outcomes.
  • Immediate Chemotherapy: In hyperleukocytosis or APL, emergent chemotherapy (e.g., hydroxyurea or specific induction for APL) may be started concurrently with or even before full diagnostic workup is complete after obtaining critical samples.

Definitive Management (Treatment Phases)

Treatment typically consists of intensive induction chemotherapy to achieve remission, followed by consolidation therapy to prevent relapse, and sometimes maintenance therapy. Allogeneic hematopoietic stem cell transplantation (HSCT) is a critical option for many patients.

• Pharmacological:
  • Acute Myeloid Leukemia (AML):
    • Induction Chemotherapy:
      • Standard (7+3 regimen): Cytarabine (100-200 mg/m²/day continuous IV infusion for 7 days) + Anthracycline (Daunorubicin 60-90 mg/m²/day or Idarubicin 12 mg/m²/day IV for 3 days). This aims to achieve complete remission (CR).
      • Targeted Therapies (added to or replacing 7+3):
        • APL (t(15;17)): All-trans retinoic acid (ATRA, 45 mg/m²/day PO) + Arsenic Trioxide (ATO, 0.15 mg/kg IV daily). This is highly curative and different from other AML types.
        • FLT3-mutated AML: Midostaurin (for younger/fit patients in combination with 7+3), or Gilteritinib (for relapsed/refractory or as single agent in unfit patients).
        • IDH1/2-mutated AML: Ivosidenib (IDH1) or Enasidenib (IDH2) for relapsed/refractory or as single agent in unfit patients.
        • *Venetoclax-based regimens (for older/unfit patients): Venetoclax (a BCL-2 inhibitor) in combination with Hypomethylating Agents (HMAs like Azacitidine or Decitabine) or low-dose Cytarabine (LDAC). This is now a standard for patients not candidates for intensive chemotherapy.
    • Consolidation Therapy: After achieving CR, to eradicate residual disease and prevent relapse. Options include:
      • High-dose Cytarabine (HDAC): Typically 1-3 g/m² IV every 12 hours for 3-5 days, repeated for 3-4 cycles.
      • Allogeneic HSCT: Often the preferred consolidation for intermediate- or adverse-risk AML patients in CR1, if eligible.
  • Acute Lymphoblastic Leukemia (ALL): A multi-phase, prolonged treatment regimen.
    • Induction: Multi-agent chemotherapy (e.g., Vincristine, Corticosteroids (Prednisone or Dexamethasone), Asparaginase, Anthracycline (Daunorubicin)). Aims to achieve CR.
    • Consolidation/Intensification: Cycles of different chemotherapy drugs (e.g., Methotrexate, Cytarabine, Etoposide, Cyclophosphamide) to deepen remission.
    • Maintenance: Long-term, lower-intensity chemotherapy (e.g., oral Mercaptopurine, oral Methotrexate, intermittent Vincristine and Prednisone pulses) for 2-3 years after induction/consolidation.
    • CNS Prophylaxis: Critical to prevent CNS relapse. Involves intrathecal chemotherapy (Methotrexate, Cytarabine, Dexamethasone) and/or cranial radiation (less common now).
    • Targeted Therapies for Specific ALL Subtypes:
      • BCR-ABL1 positive (Ph+) ALL: Tyrosine Kinase Inhibitors (TKIs) like Imatinib, Dasatinib, Ponatinib are crucial, combined with chemotherapy.
      • CD19-positive ALL (Relapsed/Refractory): Blinatumomab (bispecific T-cell engager), Inotuzumab Ozogamicin (antibody-drug conjugate), CAR T-cell therapy (e.g., Tisagenlecleucel).
• Non-pharmacological:
  • Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): Potentially curative, involves high-dose chemotherapy/radiation followed by infusion of healthy donor stem cells.
    • Indications: High-risk AML in CR1, most ALL patients in CR1 with high-risk features (e.g., Ph+ ALL, KMT2A rearrangement, poor MRD response), or relapsed/refractory AL after re-induction.
    • Types: Myeloablative vs. reduced-intensity conditioning.
  • Supportive Care: Comprehensive care including transfusions, infection prophylaxis (antimicrobial, antifungal, antiviral agents), nutritional support, pain management, psychological support.

Treatment Algorithms

• First-Line:
  • AML (Younger/Fit Patients):
    • Standard Intensive: 7+3 regimen.
    • FLT3 positive: 7+3 + Midostaurin.
    • APL: ATRA + ATO.
  • AML (Older/Unfit Patients):
    • Venetoclax + HMA (Azacitidine or Decitabine) or LDAC.
    • Single-agent HMA or LDAC.
    • Targeted agents (e.g., Ivosidenib for IDH1 mut, Enasidenib for IDH2 mut).
  • ALL (Adult):
    • Ph-negative: Multi-agent induction (Vincristine, Corticosteroids, Asparaginase, Anthracycline), followed by consolidation and maintenance. CNS prophylaxis.
    • Ph-positive: Chemotherapy + TKI.
• Second-Line (Relapsed/Refractory):
  • AML: Re-induction chemotherapy (e.g., high-dose cytarabine-based regimens like FLAG-IDA), targeted therapies (Gilteritinib for FLT3, Ivosidenib/Enasidenib for IDH1/2), venetoclax combinations, clinical trials, or allogeneic HSCT if feasible.
  • ALL: Re-induction (different agents or higher doses), Blinatumomab, Inotuzumab Ozogamicin, CAR T-cell therapy (Tisagenlecleucel for relapsed/refractory B-ALL), allogeneic HSCT.
• Refractory Cases:
  • Consider enrollment in clinical trials investigating novel agents or combinations.
  • Repeat HSCT (if prior transplant failed and patient eligible).
  • Palliative care focused on symptom management and quality of life.

Complications

Acute leukemia and its intensive treatment carry a high risk of complications.

• Common:
  • Febrile Neutropenia and Infections: Bacterial (Gram-positive and Gram-negative), fungal (Candida, Aspergillus), viral (HSV, CMV, VZV).
  • Hemorrhage: Due to thrombocytopenia or DIC.
  • Tumor Lysis Syndrome (TLS): Electrolyte abnormalities (hyperkalemia, hyperphosphatemia, hypocalcemia), hyperuricemia, acute kidney injury.
  • Mucositis/Stomatitis: Painful inflammation and ulceration of mucous membranes, especially oral cavity.
  • Nausea, Vomiting, Diarrhea: Common side effects of chemotherapy.
  • Fatigue: Profound and persistent.
• Serious:
  • Leukostasis: Life-threatening emergency (pulmonary and cerebral symptoms).
  • Disseminated Intravascular Coagulation (DIC): Especially in APL.
  • Severe Sepsis/Septic Shock: From uncontrolled infections.
  • Cardiac Toxicity: From anthracyclines (dose-dependent cardiomyopathy).
  • Neurotoxicity: From high-dose cytarabine (cerebellar syndrome), intrathecal chemotherapy, or asparaginase.
  • Veno-occlusive Disease (Sinusoidal Obstruction Syndrome - SOS): Hepatic complication, especially post-HSCT or with certain chemotherapy drugs (e.g., high-dose busulfan).
  • Graft-versus-Host Disease (GVHD): A major complication of allogeneic HSCT, where donor T-cells attack recipient tissues. Can be acute or chronic.
• Long-term:
  • Secondary Malignancies: Increased risk of solid tumors and myelodysplastic syndrome/AML.
  • Infertility: Due to gonadotoxicity of chemotherapy and radiation.
  • Organ Damage: Chronic cardiac dysfunction, renal impairment, hepatic fibrosis.
  • Neuropathy: Peripheral neuropathy from vincristine or high-dose cytarabine.
  • Cognitive Impairment ("Chemo Brain"): Memory, concentration, processing speed issues.
  • Chronic Fatigue Syndrome: Persistent fatigue.
  • Growth and Developmental Issues: In pediatric survivors.
  • Psychological Distress: Anxiety, depression, PTSD.

Prognosis

Prognosis in acute leukemia is highly variable and depends on numerous factors.

• Factors:
  • Age: Younger patients generally have better outcomes, particularly for AML.
  • Leukemia Subtype: ALL generally has better prognosis than AML in children; in adults, outcomes are more similar, but certain ALL subtypes (e.g., Ph+ ALL) or AML subtypes (e.g., APL) have unique prognoses.
  • Cytogenetics and Molecular Genetics: The most important prognostic factor.
    • AML:
      • Favorable Risk: t(8;21), inv(16) or t(16;16), NPM1 mutation without FLT3-ITD or with low FLT3-ITD allelic ratio, biallelic CEBPA mutation.
      • Intermediate Risk: Normal cytogenetics, FLT3-ITD with high allelic ratio, KIT mutations.
      • Adverse Risk: Complex karyotype, Monosomal karyotype, -5/del(5q), -7/del(7q), TP53 mutation, RUNX1 mutation, ASXL1 mutation, KMT2A (MLL) rearrangements.
    • ALL:
      • Favorable Risk: ETV6-RUNX1 (TEL-AML1) fusion, high hyperdiploidy (>50 chromosomes).
      • Intermediate Risk: Normal cytogenetics.
      • Adverse Risk: BCR-ABL1 (Ph+), KMT2A (MLL) rearrangements, hypodiploidy (<44 chromosomes), near-haploidy, IKZF1 deletions (especially with Ph-like ALL).
  • Initial WBC Count: Very high WBC (>50,000-100,000/µL) associated with poorer prognosis, increased risk of TLS and leukostasis.
  • Response to Induction Therapy: Achievement of complete remission (CR) and, critically, Minimal Residual Disease (MRD) negativity after induction are strong favorable prognostic indicators.
  • Performance Status: Better pre-treatment performance status correlates with better outcomes and tolerability of intensive therapy.
  • Presence of Extramedullary Disease: Especially CNS involvement, which is associated with higher risk of relapse.
• Survival:
  • AML (Adults): Overall 5-year survival rates are approximately 30-40%. For younger patients with favorable risk AML, 5-year survival can exceed 60-70%. For older patients or those with adverse risk, 5-year survival rates can be less than 10-20%.
  • ALL (Children): 5-year event-free survival rates exceed 90% for standard-risk ALL.
  • ALL (Adults): 5-year survival rates are approximately 40-50%. Ph+ ALL previously had poor outcomes, but with TKIs, survival has significantly improved.
• Quality of Life: Intensive treatment significantly impacts quality of life during and immediately after therapy due to side effects. Long-term survivors may experience chronic fatigue, organ dysfunction, neuropathy, cognitive issues, and psychological distress, requiring ongoing surveillance and supportive care.

Prevention

Primary prevention of acute leukemia is largely limited due to its complex and often unknown etiology.

• Primary:
  • Avoidance of Known Carcinogens: Minimize exposure to chemicals like benzene and avoid smoking.
  • Genetic Counseling: For individuals with strong family histories or known hereditary cancer syndromes associated with increased leukemia risk. However, genetic screening for general population is not recommended.
  • Responsible Use of Chemotherapy/Radiation: Judicious use of potentially leukemogenic agents in prior cancer treatment (though often unavoidable).
• Secondary:
  • No routine screening tests exist for early detection in the general population.
  • Early diagnosis once symptoms appear is critical for timely initiation of treatment.
  • For patients with Myelodysplastic Syndromes (MDS) at high risk of AML transformation, certain therapies (e.g., hypomethylating agents) may delay progression, though this is primarily treatment of MDS rather than leukemia prevention.
• Tertiary:
  • Focuses on preventing complications of the disease and its treatment, and managing long-term sequelae.
  • Infection Prophylaxis: During neutropenia (antibacterial, antifungal, antiviral).
  • TLS Prophylaxis: During induction.
  • MRD Monitoring: To guide treatment escalation and prevent relapse.
  • Long-term Follow-up: For surveillance of late effects (e.g., cardiac function, secondary malignancies, infertility).

Special Populations

• Pediatric:
  • ALL is more common in children: Accounts for ~75% of childhood leukemias.
  • Higher Cure Rates: Especially for ALL (5-year survival >90%). AML survival in children is also better than adults (60-70%).
  • Different Biology: Specific genetic subtypes common in children (e.g., ETV6-RUNX1, KMT2A rearrangements).
  • Treatment Intensification: Treatment protocols are often more intensive and prolonged, with critical CNS prophylaxis, and tailored to specific risk groups.
  • Long-term Effects: Special attention to growth and development, neurocognitive deficits, secondary malignancies, and fertility preservation.
• Geriatric (Older Adults, typically >60-65 years):
  • Higher Incidence of AML: Accounts for the majority of AML cases.
  • Less Favorable Biology: Higher prevalence of adverse-risk cytogenetics (TP53 mutations, complex karyotype), and myelodysplasia-related changes.
  • Increased Comorbidities: Higher rates of cardiovascular disease, renal dysfunction, etc., limiting tolerance to intensive chemotherapy.
  • Treatment Approach: Individualized assessment of fitness and comorbidities.
    • Intensive Chemotherapy: Only for fit patients with good performance status.
    • Lower-Intensity Regimens: For unfit patients, venetoclax combinations with HMAs (azacitidine/decitabine) or LDAC are standard first-line. HMAs alone or LDAC are alternatives.
    • Supportive Care: Emphasis on managing complications and maintaining quality of life.
• Pregnancy:
  • Rare but Challenging: Diagnosis and management are complex due to risks to both mother and fetus.
  • Diagnosis: Bone marrow biopsy is safe. Imaging with reduced radiation is preferred.
  • Treatment Decisions:
    • First Trimester: Often very difficult; may consider termination due to high risk of fetal malformations from chemotherapy.
    • Second/Third Trimesters: Chemotherapy may be considered, but specific drugs (e.g., methotrexate) are contraindicated. Standard intensive regimens (e.g., 7+3) can be given, with modifications. Delivery may be induced early if possible to allow for full chemotherapy. A multidisciplinary team approach is essential.
  • APL: ATRA can be given throughout pregnancy, with cautious use of arsenic trioxide or limited chemotherapy.
• Comorbidities:
  • Cardiac Disease: Careful monitoring of left ventricular ejection fraction (LVEF) if anthracyclines are used; dose adjustments or less cardiotoxic regimens may be needed.
  • Renal/Hepatic Dysfunction: Dose adjustments for renally or hepatically cleared drugs (e.g., cytarabine, asparaginase). Increased risk of TLS with pre-existing renal impairment.
  • Infections: Patients with pre-existing immunosuppression or chronic infections require aggressive prophylaxis and monitoring.

Clinical Pearls

• Diagnostic:
  • Always suspect acute leukemia in patients with new onset or rapidly worsening pancytopenia, unexplained fever, significant bruising/bleeding, or bone pain, especially if blasts are seen on peripheral smear.
  • Don't rely solely on automated CBC differentials: Always manually review the peripheral blood smear for blasts. A "lymphocytosis" on automated counts might actually be blasts.
  • Sternal tenderness is a classic but non-specific sign of bone marrow expansion and warrants immediate investigation.
  • Get a bone marrow biopsy and aspirate before starting therapy (unless it's an extreme emergency like APL with DIC or symptomatic leukostasis). Ensure sufficient samples are collected for morphology, flow cytometry, cytogenetics, and molecular studies.
  • APL is a medical emergency: If suspected (promyelocytes on smear, DIC), start ATRA immediately before definitive genetic confirmation (t(15;17)) to prevent life-threatening coagulopathy.
• Treatment:
  • Aggressive supportive care is paramount: Prompt management of febrile neutropenia, judicious transfusions, and vigilant TLS prophylaxis are as critical as chemotherapy.
  • Tailor therapy based on molecular and cytogenetic findings: Genetic risk stratification guides intensity of chemotherapy and indication for HSCT. Targeted therapies are now standard for specific mutations.
  • CNS prophylaxis is critical in ALL: Do not miss or delay this.
  • Monitor for TLS closely in the first few days of induction, especially in patients with high WBC, high LDH, or signs of renal impairment.
• Pitfalls:
  • Delaying diagnosis or treatment: Especially in APL or symptomatic leukostasis.
  • Underestimating the risk of infections: Fever in a neutropenic patient is an emergency; broad-spectrum antibiotics should be started within one hour.
  • Inadequate supportive care: Leading to preventable complications like severe bleeding, uncontrolled infections, or TLS.
  • Missing CNS involvement: Can lead to devastating relapses. Perform LPs as indicated.
  • Not considering patient fitness in older adults: Offering intensive chemotherapy to frail, comorbid patients can lead to high treatment-related mortality.

Recent Updates

• Guidelines:
  • WHO Classification (2022): Updated classification of myeloid and lymphoid neoplasms with refined diagnostic criteria and new entities based on molecular findings.
  • NCCN (National Comprehensive Cancer Network) Guidelines: Regularly updated comprehensive guidelines for AML and ALL, providing evidence-based recommendations for diagnosis, risk stratification, and management based on patient age, fitness, and genetic profile.
  • ASH (American Society of Hematology) Guidelines: Provide concise, actionable recommendations for specific aspects of leukemia management (e.g., management of veno-occlusive disease, MRD in AML).
• Evidence:
  • Targeted Therapies:
    • AML: Increased use of FLT3 inhibitors (Midostaurin, Gilteritinib), IDH1/2 inhibitors (Ivosidenib, Enasidenib), and BCL-2 inhibitor (Venetoclax) in combination with HMAs or low-dose cytarabine for older/unfit patients, significantly improving outcomes in these populations.
    • ALL: Continued progress with TKIs for Ph+ ALL (e.g., Ponatinib), and immune therapies like Blinatumomab, Inotuzumab Ozogamicin, and CAR T-cell therapy (Tisagenlecleucel) for relapsed/refractory CD19+ B-ALL, transforming outcomes in previously dismal settings.
  • Minimal Residual Disease (MRD): Growing evidence for MRD-guided therapy in both AML and ALL, using highly sensitive methods (e.g., multiparameter flow cytometry, PCR for fusion genes or specific mutations). MRD negativity after induction and consolidation is a strong prognostic factor and can influence decisions regarding consolidation (e.g., intensity of chemotherapy, indication for HSCT).
  • Allogeneic HSCT: Continued refinement of conditioning regimens and post-transplant strategies to reduce toxicity and improve outcomes, including the use of post-transplant cyclophosphamide for GVHD prophylaxis and targeted therapy as maintenance.
• Controversies:
  • Optimal consolidation for intermediate-risk AML: Debate on whether allogeneic HSCT is always superior to high-dose cytarabine for patients in CR1, especially those who achieve MRD negativity.
  • Role of maintenance therapy in AML: While standard for APL, the role of maintenance therapy for other AML subtypes after intensive chemotherapy or HSCT is still being actively investigated, with some targeted agents showing promise (e.g., gilteritinib post-HSCT for FLT3-mutated AML).
  • Timing of CAR T-cell therapy in ALL: Optimal sequencing of CAR T-cell therapy versus other novel agents or second HSCT for relapsed/refractory ALL.

Key References

• Guidelines:
  • National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology:
    • Acute Myeloid Leukemia (AML)
    • Acute Lymphoblastic Leukemia (ALL)
    • Supportive Care guidelines (e.g., Prevention and Treatment of Cancer-Related Infections)
    • Available at: www.nccn.org
  • World Health Organization (WHO) Classification of Tumours of Haematopoietic and Lymphoid Tissues (5th Edition). Lyon (France): International Agency for Research on Cancer; 2022.
  • American Society of Hematology (ASH) Clinical Practice Guidelines: Regularly updated guidelines on specific topics in hematology.
    • Available at: www.hematology.org/education/clinicians/guidelines
• Studies/Reviews:
  • Döhner H, Weisdorf EJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med. 2015 May 14;372(19):2016-2027. (Classic review on AML)
  • Pulte D, Redaelli M, Swerdlow AJ, et al. Cancer in Children, Adolescents, and Young Adults in Europe: An Update. Cancers (Basel). 2023 Feb 1;15(3):910.
  • Short NJ, Rytting ME, Cortes JE. Acute Lymphoblastic Leukemia: Updates on Diagnosis, Prognosis, and Treatment. J Clin Oncol. 2020 Dec 1;38(35):4053-4066.
  • Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin in FLT3-Mutated Acute Myeloid Leukemia. N Engl J Med. 2017 Aug 10;377(5):454-464. (Landmark FLT3-AML trial)
  • Wei AH, Roberts AW, Spencer A, et al. Venetoclax for newly diagnosed AML in older patients. N Engl J Med. 2020 Jan 23;382(4):307-318. (Key study on Venetoclax in AML)
  • Maude SL, Laetsch PW, Buechner S, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018 Feb 1;378(5):439-448. (Landmark CAR T-cell trial)